BC Platforms AG of Switzerland has struck another collaboration with an institution that collects anonymised data from patients, significantly expanding its repertoire of information that can be used in medical research. The collaboration is with OmicsBank, a US-based company with access to patient data from emerging markets. Specifically, the partnership will give BC Platforms rights to data from India and the United Arab Emirates, countries which have been under-represented in global pharmaceutical research. The financial terms of the collaboration were not disclosed.
The deal was announced on 5 February, just two months after BC Partners reached an agreement with GeneVault Lifesciences of Cambridge, US, to give the Swiss company access to data sources across countries in Asia and the Middle East as well as countries in Africa and Latin America. The new deal will focus on India which accounts for nearly 20% of the world’s population with a high prevalence of non-communicable diseases such as cardiovascular disease, diabetes, and cancer. The OmicsBank datasets include anonymised patient electronic medical records, pathology studies, medical images, and sequencing data.
“These datasets can be provisioned either as modular datasets for specific research use cases or as comprehensive longitudinal cohorts to support advanced analytics and the development and benchmarking of multimodal AI models in healthcare,” the company said.
BC Platforms was founded in 1997 from a project at the Massachusetts Institute of Technology, US. The company collects and analyses data on patient health from sources other than clinical settings.
Copyright 2026 Evernow Publishing Ltd